{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe binding affinity constant (KD) of M to human PD-1 specifically binds to human PD-1, said affinity preferably being determined by biosensor analysis.\n\n\nNote: Unfortunately, there is only one sentence that contains a molecule name (M), a bioactivity metric (KD), but it lacks a specific numeric value and unit for that metric. However, I extracted it as it contains some relevant information. If you'd like, I can try to re-analyze the text to see if I missed anything."}
{"final_json": [{"molecule_name": "M", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nC: IC50 values for each variant antibody measured by ELISA, binding of PD1 to PDL1 was studied in the presence of increasing concentrations of humanized anti-PD 1 variant antibody.\nB: results are shown comparing light chain LD and LC variants (HELC or HELD antibodies) in combination with HE variants of heavy chains. IC50 (ng/mL) refers to the concentration required to achieve 50% inhibition of signal.\nEC50 (\u03bc g/mL) refers to the concentration of antibody required to achieve 50% of the maximum luminescence."}
{"final_json": [{"molecule_name": "PD1", "protein_target_name": "PDL1", "binding_metric": "IC50", "value": null, "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": "HELC or HELD antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "EC50", "value": null, "unit": "\u03bcg/mL", "is_logarithmic": false}]}
{"raw_mentions": "It presents less than 10 for human PD-1 Binding affinity (KD) of M."}
{"final_json": [{"molecule_name": "M", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": "<10", "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "it has a value equal to or lower than 10 for human PD-1 Binding affinity (KD) of M;"}
{"final_json": [{"molecule_name": "M", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": "<=10", "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* The humanized anti-PD-1 antibody is equal to or less than 10 <sup>-8</sup> M, preferably equal to or lower than 10 <sup>-9</sup> M affinity of M binds to human PD-1.\n* In one aspect, the affinity is equal to or lower than 1.5x 10 <sup>-9</sup> M.\n* For example, by BlitzAnalytically, the antibodies provided herein bind to human PD-1 with an affinity constant (KD) equal to or lower than 0.75 to 1.34nM, preferably equal to or lower than 0.75 to 1nM, more preferably equal to or lower than 0.75 to 0.8 nM.\n* The humanized antibodies of the invention have an IC50 of less than 50ng/ml, particularly less than 40ng/ml and optionally less than 20ng/ml as measured by this assay.\n* In contrast, chimeric antibodies have an IC50 greater than 50ng/ml, i.e., about 60 ng/ml."}
{"final_json": [{"molecule_name": "humanized anti-PD-1 antibody", "protein_target_name": "human PD-1", "binding_metric": "affinity", "value": "<10^-8", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "affinity", "value": "1.5x 10^-9", "unit": "M", "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": "0.75 to 1.34", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": "0.75 to 1", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": "human PD-1", "binding_metric": "KD", "value": "0.75 to 0.8", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "humanized antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": "<50", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "humanized antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": "<40", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "humanized antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": "<20", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "chimeric antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": ">50", "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "chimeric antibodies", "protein_target_name": null, "binding_metric": "IC50", "value": "60", "unit": "ng/ml", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nHCLD    1.29    2.26e5    2.91e-4    nM    1/Ms    1/s\nHCLD    1.34    3.19e5    4.29e-4    nM    1/Ms    1/s\nHELD    1.14    4.43e5    5.07e-4    nM    1/Ms    1/s\nHGLD    1.28    2.74e5    3.52e-4    nM    1/Ms    1/s\nHHLD    0.84    4.05e5    3.43e-4    nM    1/Ms    1/s\nHILD    0.93    4.58e5    4.27e-4    nM    1/Ms    1/s\nHJLD    1.05    4.1e5    4.32e-4    nM    1/Ms    1/s\nHKLD    0.75    3.51e5    2.62e-4    nM    1/Ms    1/s\nHLLD    1.25    4.41e5    5.54e-4    nM    1/Ms    1/s\nHKLD    4.1 E -9    3.24 E 5    0.05137    M    1/Ms    1/s\nKEYTRUDA clinics    4.42 e -9    4.5 e 5    0.00428    M    1/Ms    1/s\n\n\nNote that I've extracted rows from tables 5 and 6, as they contain specific molecule names (e.g. HCLD, HKLD, KEYTRUDA), bioactivity metrics (e.g. KD, Ka, Kd), numeric values, and units (e.g. nM, M, 1/Ms, 1/s)."}
{"final_json": [{"molecule_name": "HCLD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.29", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HCLD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.34", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HELD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.14", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HGLD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.28", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HHLD", "protein_target_name": null, "binding_metric": "Kd", "value": "0.84", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HILD", "protein_target_name": null, "binding_metric": "Kd", "value": "0.93", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HJLD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.05", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HKLD", "protein_target_name": null, "binding_metric": "Kd", "value": "0.75", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HLLD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.25", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HKLD", "protein_target_name": null, "binding_metric": "Kd", "value": "4.1 E -9", "unit": "M", "is_logarithmic": false}, {"molecule_name": "KEYTRUDA", "protein_target_name": null, "binding_metric": "Kd", "value": "4.42 e -9", "unit": "M", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nKD(nM) Ka(1/Ms) Kd(1/s) antibody-free antibodies 1.83e-7 3.68 E4 6.71E-3 nM\nHCLD 7.15E-3 10.1 7.2E-2 nM\nHELD 5.91E-3 14.9 1.04E4 nM\nHGLD 9.8E-3 28.3 5.34E-2 nM\nHHLD 8.54E-3 112.2 1.04E-1 nM\nHILD 1.12E-3 790 88.8E-1 nM\nHJLD 2.79E-3 65.4 5.67E4 nM\nHKLD 4.59E-3 18.8 8.62E-2 nM\nHLLD 2.15E-3 99.6 2.14E-1 nM\nTable 14: the antagonist ability of PD-1 antibodies to block PD-L1 binding. IC50 (ng/ml) was determined with different humanized anti-PD 1 variant antibodies, the results are shown in FIG. 4C.\nTable 15: antagonist ability of PD-1 antibodies to block PD-1-mediated inhibitory signaling: the IC50 (ng/mL) was determined, which refers to the concentration required for signal inhibition to reach 50%, from FIG. 7A.\nTable 16: anti-PD-1 antibodies enhance T cell activation in vitro: the ED50 (\u03bc g/mL) was determined, which refers to the concentration of antibody required to achieve 50% of the maximum luminescence, from fig. 8."}
{"final_json": [{"molecule_name": "antibody-free antibodies", "protein_target_name": null, "binding_metric": "Kd", "value": "6.71E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HCLD", "protein_target_name": null, "binding_metric": "Kd", "value": "7.15E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HELD", "protein_target_name": null, "binding_metric": "Kd", "value": "5.91E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HGLD", "protein_target_name": null, "binding_metric": "Kd", "value": "9.8E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HHLD", "protein_target_name": null, "binding_metric": "Kd", "value": "8.54E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HILD", "protein_target_name": null, "binding_metric": "Kd", "value": "1.12E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HJLD", "protein_target_name": null, "binding_metric": "Kd", "value": "2.79E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HKLD", "protein_target_name": null, "binding_metric": "Kd", "value": "4.59E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "HLLD", "protein_target_name": null, "binding_metric": "Kd", "value": "2.15E-3", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "PD-1 antibodies", "protein_target_name": "PD-L1", "binding_metric": "IC50", "value": null, "unit": "ng/ml", "is_logarithmic": false}, {"molecule_name": "PD-1 antibodies", "protein_target_name": "PD-1", "binding_metric": "IC50", "value": null, "unit": "ng/mL", "is_logarithmic": false}, {"molecule_name": "anti-PD-1 antibodies", "protein_target_name": null, "binding_metric": "ED50", "value": null, "unit": "\u03bcg/mL", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nAnti-human PD1 antibody (Keytruda, opdivo, HKLD variant, chimeric) at 1.25nM was added and combined with recombinant hPD-His (Sino Biologicals, beijing, china; reference 10377-H08H) at different doses (6.25 nM to 200 nM) to calculate the binding constant (ka) and dissociation constant (KD) and determine the affinity constant KD (ka/KD).\n\n\nRecombinant hPD-His (Sino Biologicals, beijing, china; reference 10377-H08H) was immobilized on a Ni-NTA biosensor (Fort \u00e9 Bio; USA; reference 18-0029) for 30 seconds at 10. Mu.g/ml via a histidine tail. Then, the anti-PD 1 antibody was allowed to bind at 20. Mu.g/mL for 120 seconds.\n\n\nHuman recombinant PD-L2 was immobilized on the biosensor chip at a concentration of 200. Mu.g/mL. The biosensor chip was then treated with 1M PH8.4 ethanolamine for 10min to inactivate the free sites. Complex antibody (200 nM) + recombinant human PD-1 (100 nM) was added and relative responses were measured by Biacore.\n\n\nRecombinant hPD-His (Sino Biologicals, beijing, china; reference 10377-H08H) was immobilized on a Ni-NTA biosensor (Fort \u00e9 Bio; USA; reference 18-0029) for 30 seconds at 10. Mu.g/ml via a histidine tail. In the second step, PD1 was incubated with 20 \u03bc g/mL (saturating concentration) of humanized anti-PD 1 variant antibody for 120 seconds.\n\n\nRecombinant hPDL1 was immobilized on plastic at 2. Mu.g/ml in PBS pH7.4 buffer. The purified antibodies (different concentrations) were mixed with 0.66. Mu.g/ml of final (fixed concentration) biotinylated human PD1 (Acrobiosystems; USA; reference EP-101) at 37 \u2103 for 2h to measure competitive binding."}
{"final_json": [{"molecule_name": "Anti-human PD1 antibody (Keytruda, opdivo, HKLD variant, chimeric)", "protein_target_name": "hPD-His", "binding_metric": "KD", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Recombinant hPD-His (Sino Biologicals, beijing, china; reference 10377-H08H)", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Anti-PD 1 antibody", "protein_target_name": "hPD-His", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Human recombinant PD-L2", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Complex antibody + recombinant human PD-1", "protein_target_name": "PD-L2", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Recombinant hPD-His (Sino Biologicals, beijing, china; reference 10377-H08H)", "protein_target_name": "PD1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Humanized anti-PD 1 variant antibody", "protein_target_name": "PD1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Recombinant hPDL1", "protein_target_name": "PD1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Purified antibodies", "protein_target_name": "PD1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "Biotinylated human PD1 (Acrobiosystems; USA; reference EP-101)", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "None"}
